Laurus Labs gets 3 observations from USFDA for Visakhapatnam facility
Posted by
www.biotecnika.org
The company has completed the pre approval inspection (PAI) for an
active pharmaceutical ingredient (API) manufactured at its Units 1&3,
located at Visakhapatnam by the United States Food and Drug
Administration, Laurus Labs said in a filing to the BSE. The
inspection was completed with three observations, 'which are
procedural in nature'.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/laurus-labs-gets-3-observations-from-usfda-for-visakhapatnam-facility/articleshow/72171142.cms
Subscribe to:
Post Comments (Atom)
Post a Comment